Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC.
暂无分享,去创建一个
R. Kučera | O. Topolcan | O. Fiala | P. Hošek | J. Rácek | J. Finek | L. Benesova | Marek Minarik | M. Pešek | P. Stehlík | O. Sorejs | A. Celer | I. Němcová | O. Šorejs
[1] Z. Bortlíček,et al. Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence. , 2013, Anticancer research.
[2] Z. Bortlíček,et al. Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy. , 2013, Anticancer research.
[3] O. Fiala,et al. Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice. , 2012, Neoplasma.
[4] T. Ciuleanu,et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. , 2012, The Lancet. Oncology.
[5] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[6] D. Gandara,et al. Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[7] Rodrigo Dienstmann,et al. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. , 2011, The oncologist.
[8] Yi-long Wu,et al. Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study. , 2011, Lung cancer.
[9] A. Tolcher,et al. Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer , 2011, British Journal of Cancer.
[10] Jun Ma,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.
[11] O. Mir,et al. A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[12] B. Geoerger,et al. Population Analysis of Erlotinib in Adults and Children Reveals Pharmacokinetic Characteristics as the Main Factor Explaining Tolerance Particularities in Children , 2011, Clinical Cancer Research.
[13] C. Gridelli,et al. Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[14] M. Kris,et al. Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[15] J. Verweij,et al. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. , 2010, European journal of cancer.
[16] K. Stoiber,et al. Benefit of Erlotinib in Patients with Non-Small-Cell Lung Cancer Is Related to Smoking Status, Gender, Skin Rash and Radiological Response but Not to Histology and Treatment Line , 2010, Oncology.
[17] J. Ferlay,et al. Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.
[18] E. Smit,et al. Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity. , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[19] E. Smit,et al. Second-line erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): Results from a large, open-label study , 2008 .
[20] Gary Clark,et al. Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies , 2007, Clinical Cancer Research.
[21] R. Perez-soler. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. , 2006, Clinical lung cancer.
[22] Stuart Thomson,et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. , 2006, Cancer research.
[23] R. Bruno,et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure‐safety relationship in patients with non–small cell lung cancer , 2006, Clinical pharmacology and therapeutics.
[24] Renato Martins,et al. Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.
[25] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[26] Daniel Jones. Anticancer drugs: To the rescue? , 2004, Nature Reviews Drug Discovery.
[27] C. N. Coleman,et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.
[28] W. Travis,et al. The new World Health Organization classification of lung tumours , 2001, European Respiratory Journal.
[29] R. Kučera,et al. Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene. , 2016, Anticancer research.
[30] J. Kolesar,et al. Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503). , 2014, European journal of cancer.
[31] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[32] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[33] Peter Boyle,et al. Cancer incidence and mortality in Europe , 2005, Sozial- und Präventivmedizin.